ArticleLife science alliance2026
Proliferation and differentiation in intestinal organoids are balanced by ligand-modulated EGFR trafficking.
Article in Life science alliance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Encapsulation and Controlled Release of Human Spinal Cord Organoid-Derived Extracellular Vesicles for Tissue Patterning in Viscoelastic Hyaluronic Acid Hydrogels.Advanced healthcare materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidermal growth factor (EGF) signaling is associated with proliferation and tumorigenesis. Conversely, EGF-family ligands can also trigger a differentiation program, an effect attributed to ligand affinity and EGF receptor (EGFR) activity. Most of these observations have been made in immortalized cell culture experiments, whereas the mechanisms underlying EGF/EGFR-driven proliferation-differentiation dynamics in complex development and tissue self-renewal have not been addressed. We show that culturing mouse small intestinal organoids (mSIOs) without EGF enhanced EGFR expression and basal phosphorylation while maintaining a balanced development of proliferative crypts and differentiated villi. Addition of EGF or Epiregulin (EREG) triggered receptor endocytosis, reducing cell-surface levels and expression. While EGF promoted crypt proliferation, EREG promoted both proliferation and villus differentiation compared with untreated controls. Removal or re-introduction of EGF or EREG proved sufficient to induce development comparable to the constant presence of ligands over 96 h. Sub-saturating concentrations of EGF led to increased villus differentiation, resembling EREG treatments, suggesting that control over EGFR endocytic cycle regulates its plasma membrane localization shaping the balance of proliferation and differentiation in mSIOs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.